Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedicituzumab for HER2-expressing high-risk non–muscle-invasive bladder cancer (phase II)
ChiCTR2600121526Phase 2Not yet recruiting
- Sponsor
- Yantai Yuhuangding Hospital
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in bladder cancer, sponsored by Yantai Yuhuangding Hospital. Primary endpoint: Recurrence-Free Survival (RFS) at 1 and 2 years after TURBT. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
bladder cancer
Beyond the preview
Go deeper on ChiCTR2600121526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121526.